(688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Obtaining Drug Registration Approval
Filed with SSE · Stock code 688837 · · 4 pages · Chinese
Summary by 6ix AI
The drug is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. This approval enhances the company's competitive edge and sustainable development capabilities, although market conditions may affect sales.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/688837evopoint-biosciences-co-ltdannouncement-on-obtaining-drug-registration-approval
Evopoint Biosciences Co Ltd on 6ix
Earlier from Evopoint Biosciences
- (688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Opening of Dedicated Settlement Accounts for Cash Management Products Purchased with Raised Funds
- (688837)"EVOPOINT BIOSCIENCES CO., LTD."Report for Q3 2026
- (688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors
- (688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Resignation of Non-independent Director, Election of Employee Representative Director, and By-election of Member of the Audit Committee of the Board of Directors
- (688837)"EVOPOINT BIOSCIENCES CO., LTD."Announcement on Change of Securities Affairs Representative
Follow Evopoint Biosciences into a list and get an email when it puts out news.
Follow Evopoint Biosciences